Cargando…

Analyses of Potential Predictive Markers and Survival Data for a Response to Sunitinib in Patients with Metastatic Renal Cell Carcinoma

BACKGROUND: Patients with metastatic clear cell renal cell carcinoma (ccRCC) are frequently treated with tyrosine kinase inhibitors (TKI) such as sunitinib. It inhibits angiogenic pathways by mainly targeting the receptors of VEGF and PDGF. In ccRCC, angiogenesis is characterized by the inactivation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dornbusch, Juana, Zacharis, Aristeidis, Meinhardt, Matthias, Erdmann, Kati, Wolff, Ingmar, Froehner, Michael, Wirth, Manfred P., Zastrow, Stefan, Fuessel, Susanne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3785463/ https://www.ncbi.nlm.nih.gov/pubmed/24086736 http://dx.doi.org/10.1371/journal.pone.0076386

Ejemplares similares

Stage-dependent prognostic impact of molecular signatures in clear cell renal cell carcinoma
por: Weber, Thomas, et al.
Publicado: (2014)

Lack of Ephrin Receptor A1 Is a Favorable Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma
por: Toma, Marieta I., et al.
Publicado: (2014)

Enhanced Inhibition of Bladder Cancer Cell Growth by Simultaneous Knockdown of Antiapoptotic Bcl-xL and Survivin in Combination with Chemotherapy
por: Kunze, Doreen, et al.
Publicado: (2013)

Simultaneous siRNA-mediated knockdown of antiapoptotic BCL2, Bcl-xL, XIAP and survivin in bladder cancer cells
por: KUNZE, DOREEN, et al.
Publicado: (2012)

Elevated expression of prostate cancer-associated genes is linked to down-regulation of microRNAs
por: Erdmann, Kati, et al.
Publicado: (2014)

Urinary MicroRNAs as Potential Markers for Non-Invasive Diagnosis of Bladder Cancer
por: Erdmann, Kati, et al.
Publicado: (2020)

Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis
por: Fuessel, Susanne, et al.
Publicado: (2014)

Carbon nanomaterials sensitize prostate cancer cells to docetaxel and mitomycin C via induction of apoptosis and inhibition of proliferation
por: Erdmann, Kati, et al.
Publicado: (2017)

Evaluation of MicroRNAs as Non-Invasive Diagnostic Markers in Urinary Cells from Patients with Suspected Prostate Cancer
por: Borkowetz, Angelika, et al.
Publicado: (2020)

Predicting 90-day and long-term mortality in octogenarians undergoing radical cystectomy
por: Froehner, Michael, et al.
Publicado: (2018)

Angiogenic, inflammatory and immunologic markers in predicting response to sunitinib in metastatic renal cell carcinoma
por: Mizuno, Ryuichi, et al.
Publicado: (2017)

Validation of the diagnostic utility of urinary midkine for the detection of bladder cancer
por: Vu Van, Dana, et al.
Publicado: (2016)

Targeted Quantification of Carbon Metabolites Identifies Metabolic Progression Markers and an Undiagnosed Case of SDH-Deficient Clear Cell Renal Cell Carcinoma in a German Cohort
por: William, Doreen, et al.
Publicado: (2021)

Induction of trismus by sunitinib and pazopanib in metastatic renal cell carcinoma
por: Iyer, Ridhima, et al.
Publicado: (2017)

Complete remission of metastatic renal cell carcinoma to the bone with sunitinib
por: Yoshimura, Akihiro, et al.
Publicado: (2020)

Metastatic atypical renal tumour with metanephric characteristics treated with Sunitinib
por: Mohammad, H., et al.
Publicado: (2021)

High serum levels of Dickkopf-1 are associated with a poor prognosis in prostate cancer patients
por: Rachner, Tilman D, et al.
Publicado: (2014)

Sunitinib in metastatic thymic carcinomas: Laboratory findings and initial clinical experience
por: Ströbel, P, et al.
Publicado: (2010)

Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers
por: Kontovinis, Loukas F, et al.
Publicado: (2009)

Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to Sunitinib in metastatic renal cancer
por: Rossi, E, et al.
Publicado: (2012)

Predictive Immunohistochemical Markers Related to Drug Selection for Patients Treated with Sunitinib or Sorafenib for Metastatic Renal Cell Cancer
por: Ma, Xin, et al.
Publicado: (2016)

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma
por: Hutson, T E, et al.
Publicado: (2014)

Buccodental side effects of sunitinib in patients with metastatic renal cell carcinoma
por: Gilabert, M, et al.
Publicado: (2013)

Intolerance to Sunitinib Treatment in Hemodialysis Patients With Metastatic Renal Cell Carcinoma
por: Yildiz, Ibrahim, et al.
Publicado: (2014)

Clinical significance of sunitinib‐associated macrocytosis in metastatic renal cell carcinoma
por: Bourlon, Maria T., et al.
Publicado: (2016)

The role of netrin-1 in metastatic renal cell carcinoma treated with sunitinib
por: Frees, Sebastian, et al.
Publicado: (2018)

Erythema multiforme major induced by sunitinib for metastatic renal cell carcinoma
por: Watanabe, Daisuke, et al.
Publicado: (2019)

Role of WNT5A receptors FZD5 and RYK in prostate cancer cells
por: Thiele, Stefanie, et al.
Publicado: (2018)

Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients
por: Ordu, Çetin, et al.
Publicado: (2016)

Diffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinoma
por: Bharwani, N, et al.
Publicado: (2014)

Clinical implications of pharmacokinetics of sunitinib malate and N-desethyl-sunitinib plasma concentrations for treatment outcome in metastatic renal cell carcinoma patients
por: Numakura, Kazuyuki, et al.
Publicado: (2018)

Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis
por: Wen, Tingyu, et al.
Publicado: (2017)

Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib
por: Billemont, B, et al.
Publicado: (2008)

Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
por: Molina, Ana M., et al.
Publicado: (2010)

An Unusual Metastatic Renal Cell Carcinoma with Maintained Complete Response to Sunitinib Treatment
por: Chara, Luis, et al.
Publicado: (2011)

A case of metastatic renal cell carcinoma treated effectively by gemcitabine and sunitinib
por: Morizane, Shuichi, et al.
Publicado: (2012)

Sequential Treatment Based on Sunitinib and Sorafenib in Patients with Metastatic Renal Cell Carcinoma
por: Schlemmer, Marcus, et al.
Publicado: (2019)

Ιmpact of sunitinib-induced hypothyroidism on survival of patients with metastatic renal cancer
por: Vasileiadis, Theofanis, et al.
Publicado: (2019)

Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma
por: Blagoev, Krastan B., et al.
Publicado: (2013)

Survival in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib With or Without Cryoablation
por: Gu, Cheng-Yuan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fum64qa7bsq92ob2rti1ei0ghb